MARKETING
We have made it our goal, to if not eradicate, - make a significant contribution towards battling the global cancer epidemic. Our drug will be marketed first in the North American market early in the coming year. We envisage a vast growth projection given the revolutionary nature of our product. We will conduct our marketing campaign through many avenues. We are currently liaising with the OmnicomMediaGroup® to help construct a marketing strategy that suits our company and product vision the best. This will be accomplished through the television, print and viral/internet media communications. Using the North American market as our blueprint, we will then add the remaining markets as quickly as is feasible. Adenogen™ will be priced at 100 dollars. A very attainable figure we feel and, after the initial three injections spread over two weeks, shall only require re-administering after a ten-year period as in gene therapy it is not possible to have a gene expressed in a foreign body for life. The longest that has ever been expressed is 15 years and through our research we estimated that our product will expressed in the body for up to ten years. We believe our products Unique Selling Point is the price, we want to make our product affordable for everyone as we believe in building a better tomorrow.
Our chosen cell line contains 7.5 million cells per ml. Each batch uses 1000ml of CHO cell line. Each cell produces 100,000 viral particles. Single run of the bioreactor produces 750 billion viral particles. During the purification process around 20% of the yield is lost, bringing the viral particle count down to 600 billion. Considering that every vaccine contains 7.5 million viral particles of rAAV. This mean that each run would produce 80 thousand vaccines. With current population of 7.5 billion people and the need of 3 vaccinations to ensure its’ effectivity, we estimate that we will need 22.5 billion vaccines. This number will be achieved after 281,250 runs of this process. Although this does sound like a huge amount of runs to done, eventually this process can be scaled up decreasing the production costs. Our current estimated market value for this product is approximately 200 billion USD. This is 135% of estimated 147 billion USD 2018 cancer market value.
ADENOGEN
We have decided to use the technologies of gene therapy to potentially treat and prevent cancer. Gene therapy is new and upcoming technique that replacing genes that have been mutated due to either genetic makeup or the environment, with a healthy and functional copy of the gene. There has also been tested carried out which can inactivate a mutated gene which is not operating correctly. As well the idea of introduction a new gene into the body so it can begin to fight a disease has been researched. In the past there has been many clinical trials carried out but nothing has ever been released onto the market. We at Celltech believe we have come up with a process design that will be able to achieve the ideas above and we can be the first company to release a therapeutic gene product onto the market. We are thrilled to announce that through our research and development, we have produced a novel strain of the Adeno-associated virus that can replace mutated cancerous genes with those that are healthy and functional.
OUR DREAM
Here at Celltech, the many possible avenues that BIOplus could explore in the future were considered, such as motor neurons and Alzheimer’s. However, considering the currents trends, the next big recombinant based pharmaceutical bioprocess is Cancer gene therapy. The desire for such a pharmaceutical can be understood when one considers that almost 39% of the worlds’ population will contract a form of cancer within their lifetime. Cancer is a worldwide issue and can affect any living person, the technology for treating and preventing cancer is very limited at this moment in time for example there is surgery to remove the tumours, chemotherapy and/or radiation. However, these are very damaging to the body and not 100% successful, so we have set ourselves the goal of changing that. We want to tackle cancer head on and design a solution to successfully treat the disease. Cancer is a viscous disease which causes abnormal cell growth. It causes the cell in our body to grow rapidly when we don’t need them to and also stop cells from dying when we need them to. When this occurs a tumour forms and the cells of the tumour begin to spread throughout the body through the lymphatic system and the bloodstream. Depending on the type of cancer there are different ways it kills you, for example if cancer occurs in the digestive system the tumour can prevent food from entering it and causes food not being absorbed into the body. Likewise, if cancer occurs in the lungs eventually over time the amount healthy cells will be less than the cancer cells and cause lung failure.